Estimating the direct and indirect costs associated with Parkinson's disease.
about
Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience.Average annual cost of Parkinson's disease in São Paulo, Brazil, with a focus on disease-related motor symptoms.Fall-related healthcare use and costs in neurogenic orthostatic hypotension with Parkinson's disease.Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation.
P2860
Estimating the direct and indirect costs associated with Parkinson's disease.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Estimating the direct and indirect costs associated with Parkinson's disease.
@en
type
label
Estimating the direct and indirect costs associated with Parkinson's disease.
@en
prefLabel
Estimating the direct and indirect costs associated with Parkinson's disease.
@en
P2093
P2860
P1476
Estimating the direct and indirect costs associated with Parkinson's disease
@en
P2093
Luis Lizán
Pablo Martínez-Martín
Silvia Paz
P2860
P304
P356
10.1586/14737167.2015.1103184
P577
2015-10-29T00:00:00Z